Nantahala Capital Management LLC boosted its holdings in shares of Aileron Therapeutics, Inc. (NASDAQ:ALRN – Free Report) by 82.1% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 464,367 shares of the company’s stock after acquiring an additional 209,367 shares during the quarter. Nantahala Capital Management LLC owned 2.15% of Aileron Therapeutics worth $1,286,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Warberg Asset Management LLC purchased a new position in shares of Aileron Therapeutics during the second quarter worth approximately $86,000. Texas Capital Bank Wealth Management Services Inc lifted its holdings in shares of Aileron Therapeutics by 65.9% in the 1st quarter. Texas Capital Bank Wealth Management Services Inc now owns 26,171 shares of the company’s stock worth $174,000 after buying an additional 10,398 shares during the period. Finally, University of Texas Texas AM Investment Management Co. bought a new position in shares of Aileron Therapeutics during the 2nd quarter worth $4,925,000. Hedge funds and other institutional investors own 90.89% of the company’s stock.
Aileron Therapeutics Price Performance
ALRN stock opened at $3.54 on Tuesday. The company has a market capitalization of $76.52 million, a P/E ratio of -1.11 and a beta of 2.33. The business has a 50-day moving average price of $2.59 and a 200 day moving average price of $3.57. Aileron Therapeutics, Inc. has a 1-year low of $1.01 and a 1-year high of $7.42.
Aileron Therapeutics Company Profile
Aileron Therapeutics, Inc, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).
Featured Stories
- Five stocks we like better than Aileron Therapeutics
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- TJX Stock: A Buying Opportunity Before the Holiday Rush
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge
- Business Services Stocks Investing
- Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth
Want to see what other hedge funds are holding ALRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aileron Therapeutics, Inc. (NASDAQ:ALRN – Free Report).
Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.